Zydus Lifesciences

Price chart

Previous close

₹1,199.50

Open

₹1,203.20

Day high

₹1,232.30

Day low

₹1,195.90

Listed on NSE since 18 April 2000.

Futures and options

Futures, 23 Nov expiry

₹1,213.00

Premium to the share price

+3.10 (+0.26%)

Futures open interest

21,078 contracts (−17 today)

Lot size (NOV 26)

450 shares

Source: NSE, 09-Nov-2026 12:04:33, delayed. Option chain · All futures · Lot sizes

Pivot levels

R3

1,224.43

R2

1,215.97

R1

1,206.93

CPR top

1,198.75

Pivot

1,198.47

CPR bottom

1,198.18

S1

1,189.43

S2

1,180.97

S3

1,171.93

From Friday 6 November’s high, low and close (Yahoo Finance). Arithmetic on past prices, not a forecast.

Market value

₹1,19,491 Cr

P/E (trailing)

28.62

EPS (trailing)

₹41.85

Price to book

4.29

Dividend yield

0.08%

Return on equity

14.7%

Debt to equity

0.46

Profit margin

13.8%

Beta

0.31

Volume today

7.97 L

Average volume

16.70 L

Source: Yahoo Finance. Ratios use the latest reported (trailing twelve-month) figures.

Source: Yahoo Finance, from annual reports. Consolidated where reported.

Source: Zydus Lifesciences’s results filed with NSE, consolidated (the whole group). Net profit is the share of Zydus Lifesciences’s own shareholders where the filing separates it. Profit vs year ago compares with the same quarter a year earlier; – where that quarter is not on file or made a loss.

Download results (zip) A spreadsheet of the quarterly results and balance sheets, with the original filings from NSE.

Source: Zydus Lifesciences’s half-yearly statements of assets and liabilities filed with NSE, consolidated. Companies file these every September and March.

Zydus Lifesciences Limited engages in the research, development, production, marketing, distribution, and sale of pharmaceutical products in India, the United States, Europe, and internationally. It operates through three segments: Pharmaceuticals, Consumer Products, and Medical Technologies. The company offers active pharmaceutical ingredients, human and finished dosage formulations, generics, branded generics, specialty formulations, biosimilars, vaccines, novel therapeutics, medical devices and technologies, consumer wellness, veterinary, and animal health products. It also provides biological products in the areas of oncology, autoimmune disorders, nephrology, inflammation, rheumatology, hepatology, and infectious diseases; and designs and executes clinical trials across new chemical entities (NCEs), biologics, vaccines, and specialty generics. In addition, the company operates seasonal, skin and healthcare, and food and nutrition products under the Glucon D, Complan, Sugar Free, Nycil, Everyuth, Nutralite, and RiteBite Max Protein brands. The company was formerly known as Cadila Healthcare Limited and changed its name to Zydus Lifesciences Limited in February 2022. Zydus Lifesciences Limited was founded in 1952 and is headquartered in Ahmedabad, India. Zydus Lifesciences Limited is a subsidiary of Zydus Family Trust.

Industry

Drug Manufacturers - Specialty & Generic

Based in

Ahmedabad

Employees

29,980

Company website · Profile: Yahoo Finance

• Zydus Lifesciences' Saroglitazar shows higher MASH resolution rates than placebo in phase 2b trial

  CNBC-TV18 · 6 Nov, 23:35

• Dividend - Re 1 Per Share

  Dividend · ex-date 24 July 2026

• Buy Back

  Buyback · ex-date 29 May 2026

• Dividend - Rs 11 Per Share

  Dividend · ex-date 25 July 2025

• Dividend - Rs 3 Per Share

  Dividend · ex-date 26 July 2024

• Buy Back

  Buyback · ex-date 23 February 2024

• Dividend - Rs 6 Per Share

  Dividend · ex-date 28 July 2023

• Dividend - Rs 2.50 Per Share

  Dividend · ex-date 28 July 2022 · record date 29 July 2022

• Buyback

  Buyback · ex-date 1 June 2022 · record date 2 June 2022

Source: NSE. Latest first, 8 of 20.